Head-To-Head Contrast: Connect Biopharma (NASDAQ:CNTB) versus Artiva Biotherapeutics (NASDAQ:ARTV)

Connect Biopharma (NASDAQ:CNTB) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Connect Biopharma and Artiva Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

Volatility and Risk

Connect Biopharma has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500. Comparatively, Artiva Biotherapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500.

Institutional and Insider Ownership

58.7% of Connect Biopharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Connect Biopharma and Artiva Biotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1	0	8	0	2.78
Artiva Biotherapeutics	1	4	2	0	2.14

Connect Biopharma currently has a consensus target price of $5.88, suggesting a potential upside of 595.02%. Artiva Biotherapeutics has a consensus target price of $24.80, suggesting a potential upside of 479.44%. Given Connect Biopharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe Connect Biopharma is more favorable than Artiva Biotherapeutics.

Valuation & Earnings

This table compares Connect Biopharma and Artiva Biotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$2.95 million	18.03	-$55.48 million	($1.19)	-0.71
Artiva Biotherapeutics	$250,000.00	837.00	-$83.86 million	($3.30)	-1.30

Connect Biopharma has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Connect Biopharma beats Artiva Biotherapeutics on 9 of the 13 factors compared between the two stocks.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.